VASO — what changed in the latest 10-Q
A section-by-section comparison of VASO's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +47 | −24 | ~6 | 4 |
| Controls & procedures | Text added/removed | 0 | 0 | ~4 | 0 |
| Legal proceedings | Text added/removed | 0 | 0 | ~1 | 0 |
| Other information | Text added/removed | +5 | −3 | ~2 | 11 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Risk factors
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
●IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc. (“VasoTechnology”), primarily focuses on managed network technology services. As described in Note C, the NetWolves managed network services operations are reported as discontinued operations and no longer included in segm…
●Equipment segment, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively, primarily focuses on the design, manufacture, sale and service of…
The Company has ended its operations in the IT segment after the sale of VHC-IT in November 2025 and the sale of NetWolves in July 2026.
Unless otherwise noted, this Management’s Discussion and Analysis of Financial Condition and Results of Operations relates solely to our continuing operations and does not include the operations of NetWolves. See Note C – Discontinued Operations of the notes to condensed consolidated financial state…
Results of Operations – For the Three Months Ended June 30, 2026 and 2025
Text removed vs the prior filing · source: 10-Q · 2026-05-15
●IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc. (“VasoTechnology”), primarily focuses on managed network technology services. We divested our former healthcare IT service business in November 2025;
●Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp.…
Results of Operations – For the Three Months Ended March 31, 2026 and 2025
Total revenue for the three months ended March 31, 2026 and 2025 was $19,356,000 and $19,462,000, respectively, representing a decrease of $106,000, or less than 1% year-over-year. On a segment basis, revenue in the professional sales service and equipment segments increased $530,000 and $118,000, r…
Revenue in the IT segment for the three months ended March 31, 2026 was $9,561,000 compared to $10,315,000 for the three months ended March 31, 2025, a decrease of $754,000, or 7%, of which $987,000 resulted from the divestiture of the VasoHealthcare IT business in the 4th quarter of 2025, partially…
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-14
3(ii) Bylaws (Incorporated by reference to Registration Statement on Form S-18, No. 33-24095).
10.1 Transaction Award Agreement between Vaso Corporation and Peter Castle
10.2 Amendment to Transaction Award Agreement between Vaso Corporation and Peter Castle
31.1 Certification of the Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Text removed vs the prior filing · source: 10-Q · 2026-05-15
3(ii) Amended and Re-stated Bylaws (Incorporated by reference to Report on Form 8-K filed February 12, 2026).
31.1 Certification of the Chief Executive Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice